Loading organizations...
§ Private Profile · Seattle, WA, USA
Software platform for laboratory inventory and project management, enabling life scientists to record, analyze, track, and collaborate efficiently.
Founded in 2018 by Jacob Lee and Jin Choe, Genemod provides a venture-funded SaaS platform for laboratory inventory and project management that helps life scientists record data, visualize projects, and collaborate efficiently. The software addresses inefficient, siloed research processes to enable better decision-making, serving institutional customers like the University of Washington School of Medicine, the University of California Berkeley, and the National Institutes of Health. Operating with 21 to 40 employees, the company raised a $1.7 million oversubscribed seed round backed by lead investor Defy.vc, which resulted in Neil Sequeira joining the board. Additional backing came from Canaan Partners, Unpopular Ventures, Omicron, and Underdog Labs, while the firm participated in the first cohort of the Venture Out Startups Launch Lab. Furthermore, Genemod has partnered with research institutions on federal grants to support pandemic response efforts.
Genemod has raised $7.0M across 2 funding rounds.
Genemod has raised $7.0M in total across 2 funding rounds.
Genemod has raised $7.0M in total across 2 funding rounds.
Genemod's investors include Defy Partners, LDV Partners, Owl Ventures, Cercano Management, Dolby Family Ventures, Canaan Partners, Omicron, Underdog Labs, Unpopular Ventures.
Genemod has raised $7.0M across 2 funding rounds. Most recently, it raised $5.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2023 | $5M Seed | Defy Partners, LDV Partners | OWL Ventures, Cercano Management, Dolby Family Ventures | Announced |
| Oct 1, 2020 | $2M Seed | Defy Partners | OWL Ventures, Canaan Partners, Omicron, Underdog Labs, Unpopular Ventures | Announced |
Genemod is a venture-backed technology company founded in 2018 that builds a cloud-based Laboratory Information Management System (LIMS) and Electronic Lab Notebook (ELN) platform tailored for biotech R&D.[1][2][3] It serves scientists, researchers, and lab managers in biopharma, cell & gene therapy, diagnostics, academia, clinical research organizations, biomanufacturing facilities, and biorepositories by centralizing inventory tracking, experiment management, protocol creation, and reporting in a single unified system.[1][3][5] The platform solves key pain points like manual data entry, siloed information across labs, low reproducibility due to duplicated experiments, and administrative burdens, enabling real-time collaboration, resource optimization, and reduced operational costs so teams can focus on breakthroughs.[1][4][5] With over $10M in funding and thousands of users, Genemod demonstrates strong growth through tiered pricing for startups to enterprises and features like customizable dashboards, freezer visualizations, and project coordination.[1][2][5]
Genemod was founded in 2018 and is headquartered in Seattle, Washington, as a response to the complexities of modern life sciences R&D, where teams generate massive data but struggle with organization, interoperability, and reproducibility.[2][5] While specific founders are not detailed in available sources, the company's leadership includes CTO Jin Choe, who has highlighted partnerships for scaling development amid talent shortages.[2] The idea emerged from recognizing that digital transformation in labs was underway but hindered by outdated tools, contaminated samples, misidentified cell lines, and unnecessary duplicate experiments that delay drug development and inflate costs.[4][5] Early traction came from addressing these gaps with a user-friendly, scalable platform integrating scientific and management tools, leading to venture backing and rapid adoption by research teams seeking intuitive collaboration solutions.[2][5]
Genemod sets itself apart in the lab software space through:
Genemod rides the wave of lab digital transformation and AI-driven life sciences R&D acceleration, where exploding data volumes from therapeutics development demand interoperable tools to combat low reproducibility rates (a major hurdle in drug discovery) and enable faster pre-clinical progress.[4][5] Timing is ideal amid post-pandemic biotech booms in cell/gene therapies, diagnostics, and biomanufacturing, where market forces like rising R&D costs and regulatory pressures favor cloud-native platforms that automate admin tasks and foster data reuse.[1][2][5] By influencing the ecosystem through community-building and tools that "put people first," Genemod helps research teams avoid wasteful duplicates, improve compliance, and scale globally, positioning it as a key enabler in the shift to flexible, collaborative "labs of the future."[3][5]
Genemod is poised for expansion by deepening integrations with emerging AI for data analytics and automation, capitalizing on biotech's data explosion to further cut reproducibility issues and speed medicine development.[5] Trends like remote collaboration, enterprise-scale biopharma adoption, and interoperability standards will shape its path, potentially amplifying its $10M+ funding into multi-fold growth via international markets and advanced features.[1][2] Its influence may evolve from a productivity booster to a foundational platform in lab ecosystems, empowering more breakthroughs as teams leverage its centralized intelligence—echoing its core mission to free scientists for what they do best.[5]